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Loss-of-function (LOF) (i.e., nonsense, splice site,
and frameshift) variants that lead to disruption of
gene function are likely to contribute to the etiology
of neuropsychiatric disorders. Here, we perform a
systematic investigation of the role of both de novo
and inherited LOF variants in schizophrenia using
exome sequencing data from 231 case and 34 con-
trol trios. We identify two de novo LOF variants in
the SETD1A gene, which encodes a subunit of his-
tone methyltransferase, a finding unlikely to have
occurred by chance, and provide evidence for a
more general role of chromatin regulators in schizo-
phrenia risk. Transmission pattern analyses reveal
that LOF variants are more likely to be transmitted
to affected individuals than controls. This is espe-
cially true for private LOF variants in genes intolerant
to functional genetic variation. These findings high-
light the contribution of LOF mutations to the genetic
architecture of schizophrenia and provide important
insights into disease pathogenesis.
INTRODUCTION
Schizophrenia (SCZ) is a severe, common psychiatric disorder
with a strong genetic component (Rodriguez-Murillo et al.,
2012). Elucidating the genomic architecture of SCZ and identi-
fying specific risk genes and affected pathways can inform the
underlying disease pathophysiology and lead to identification
of novel treatment targets.
Recent findingsmake increasingly clear that rare de novo copy
number variants (CNVs) and de novo protein-altering mutations
(defined as point substitutions or single-nucleotide variants
[SNVs] and small insertions/deletions [indels]) contribute to the
risk of SCZ and a number of other brain disorders, such as autism
and intellectual disability (Karayiorgou et al., 1995; Kirov et al.,
2012;Malhotra et al., 2011; Xuet al., 2008;deLigt et al., 2012;Gir-
ard et al., 2011; Gulsuner et al., 2013; Iossifov et al., 2012; Neale
et al., 2012; O’Roak et al., 2012b; Rauch et al., 2012; Sanderset al., 2012; Xu et al., 2011, 2012). De novo mutations are often
transmitted by relatively asymptomatic carriers in afflicted fam-
ilies (Karayiorgou et al., 2012; Rodriguez-Murillo et al., 2012),
thus contributing to the heritable component of these disorders.
The relative contribution of de novoor inheritedmutations toeach
disorder remains to be determined, but it is expected to correlate
with the impact of the disease on fitness and fecundity. Thus,
investigation of both variant types should be particularly impor-
tant for diseases with partial reduction in fecundity, such as
SCZ. Among de novo and inherited variants, ones that lead to
loss-of-function (LOF) by disrupting protein-coding genes have
a high probability of being deleterious and are of great interest
in disease etiology (Veltman and Brunner, 2012).
This study was designed to evaluate the role that de novo and
inherited LOF variants play in conferring SCZ risk. First, our inves-
tigation of the impact of de novo variation confirmed an excess of
de novo LOFs in SCZ patients and led to the identification of a
candidate risk gene (SETD1A) harboring two de novo LOF indels
in two individuals with SCZ. Second, our investigation of the
impact of transmitted variation revealed a relative increase in
the transmission of private and rare LOF variants to SCZ
probands compared to controls, especially in genes that are
more intolerant to functional genetic variation. Collectively, these
findings highlight the contribution of LOFmutations to the genetic
architecture of SCZ and provide important insights into disease
pathogenesis.
RESULTS
Systematic Search for De Novo LOF Indels Identifies
Two Mutations in SETD1A
Recently, we sequenced a total of 795 exomes from 231 parent-
proband case trios enriched for sporadic SCZ cases, as well as
34 control trios (Xu et al., 2012), and usingGATK (McKenna et al.,
2010) and Dindel (Albers et al., 2011) we identified 14 indels (ten
frameshift and four in-frame variants) with a validation rate of
20%. The low accuracy of variant calls for de novo indels
suggested that we might have missed a considerable number
of indels, including LOF frameshift indels. Here, we undertake
a more extensive analysis of de novo LOF indels, using two
recently developed software packages specifically designed to
detect indels from high-throughput sequencing data by applyingNeuron 82, 773–780, May 21, 2014 ª2014 Elsevier Inc. 773
Table 1. List of the Newly Identified De Novo Loss-of-Function Variants in 265 Trios
Position (hg19) Reference / Variant Allele Type Effect Property Gene Pop. Diagnosis
chr1:3753245-3753259 CAGGGACTCTGCTG / - D Canonical splice
site + Inframe
c.1120-3_1131 del,
p.A374_L377 del
CEP104 U.S. SCZAFF
chr12: 26816636-26816638 CTG / AGGTCAGTGTC D + I Frameshift c.1693_1695 del3ins11,
p.Q565fs
ITPR2 Afr. SCZ
chr12: 57843366 A / - D Frameshift c.619 del1, p.Q207fs INHBC Afr. SCZAFF
chr16: 30976335 C / - D Frameshift c.1272 del1, p.D424fs SETD1A Afr. SCZ
chr16: 30992058-30992059 AG / - D Canonical splice site c.4582-2_4582-1 del2 SETD1A U.S. SCZ
D, deletion; I, insertion, Afr., Afrikaner; SCZ, schizophrenia; SCZAFF, schizoaffective disorder.
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Loss-of-Function Variants in Schizophreniasplit-read-based methods, PRISM (Jiang et al., 2012) and Pindel
(Ye et al., 2009). Initial variant calling using PRISM and Pindel
produced 24 and 36 candidate de novo LOF indels, respectively.
Of these, 16 candidates overlapped (for a total of 44 unique in-
dels using the two programs), and all of the ten LOF indels vali-
dated in our previous study (nine in cases and one in controls)
(Xu et al., 2012) were included among them (Figure S1 available
online). The remaining 34 candidates for previously unidentified
de novo LOF indels (29 in cases and five in controls) were manu-
ally inspected using the Integrative Genomics Viewer (Robinson
et al., 2011) for supporting reads in the proband but not in either
of the parents. Twenty candidates in cases and all five candi-
dates in controls were excluded by this step due to lack of reads
supporting the indel in the proband or existence ofmultiple reads
supporting the indel in either of the parents. We tested the
remaining nine candidates by Sanger sequencing, and five de
novo LOF indels (all in cases) were validated (Table 1). (A com-
plete list of de novo LOF mutations in our cohort is shown in
Table S1.) The total number of individuals carrying de novo
LOF variants (nonsense, splice site, and frameshift variants) in
our case and control data sets were, respectively, 25 and 1, re-
sulting in a 3.7-fold enrichment of de novo LOFmutation carriers
in SCZ subjects (25/231; 10.8% in cases and 1/34; 2.9% in con-
trols), although the enrichment is not statistically significant. We
also asked whether the load of de novo LOF variants correlates
with any of four available clinical variables (severity of the disease
[based on clinical course and functional outcome, see Supple-
mental Experimental Procedures for detailed information], age
at disease onset, history of childhood learning disabilities, and
comorbidity of mental retardation). We observed a significant
correlation between history of childhood learning difficulties
and the number of de novo LOF variants per individual (p =
0.0006, Spearman’s rank correlation r = 0.26), indicating a higher
incidence of childhood learning difficulties in patients with de
novo LOF variants.
Notably, two of the five validated LOF indels were found in the
samegene,SETD1A (Figure 1),with twocaseprobands eachcar-
rying a frameshift de novo indel and a de novo indel changing the
canonical splice acceptor site sequence from AG to GG. The
other three validated de novo LOF indels were located within
the CEP104, ITPR2, and INHBC genes (Table 1 and Figure S2).
SETD1A encodes for a component of a histone methyltransfer-
ase complex that producesmono-, di-, and trimethylated histone
H3 at Lysine 4 (H3K4) (Miller et al., 2001; Roguev et al., 2001). The
de novo frameshift indel (D424fs) in the first proband creates an774 Neuron 82, 773–780, May 21, 2014 ª2014 Elsevier Inc.early stop codon and leads to a predicted protein truncation.
The de novo indel changing the canonical splice acceptor site
(c.4582-2_4582-1 del2 variant) in the second proband is pre-
dicted to lead to loss of exon 16 and disruption of N-SET domain
that plays an important role for H3K4 methyltransferase activity
(Dehe´ et al., 2006; Schlichter and Cairns, 2005). We used a rather
conservative approach to assess the statistical significance of
observing at least two de novo LOF mutations in the same gene
that takes into account the length of the gene and the gene-spe-
cific GC content. Based on the number of de novo LOFs found in
our cases (a total of 25: 18 coding LOFs [nonsense SNVs and
frameshift indels] and 7 splice site LOFs [canonical splice site
SNVs and indels affecting canonical splice site]), we determined
that two ormore de novo LOFmutations in a single genewere un-
likely to occur by chance (p = 0.035). As mentioned above,
because increased rates of de novo LOFs in patientswith psychi-
atric disorders have now been reported in most of the published
exome studies in psychiatric and neurodevelopmental disorders,
this is a conservative analysis since it conditions on the number of
observed de novo LOF mutations in cases (Girard et al., 2011;
Iossifov et al., 2012; O’Roak et al., 2012b; Sanders et al., 2012;
Xu et al., 2011, 2012). We used an additional method to evaluate
the significance of observing at least two LOF de novomutations
in SETD1A, which results in a p value that is specific to SETD1A.
Specifically, we first estimated the probability of an LOF de novo
mutation per chromosome for SETD1A and then used a Poisson
model for the probability of observing two or more LOF de novo
events in this gene. The key element in this calculation is speci-
fying the mutation rate for SETD1A. To achieve this, we made
use of the recently developed transmission and de novo asso-
ciation (TADA) software (He et al., 2013), which estimates themu-
tation rate per gene based on its exonic length and its nucleotide
content (Sanders et al., 2012). For SETD1A, we obtained an LOF
mutation rate per chromosome of 4.75 3 106. The resulting
probability of twoormore LOFmutations is 2.43 106. Assuming
that there are 20,000 genes, the genome-wide p value is 0.048,
very similar to our first analysis.
Considering the phenotypic presentation of the mutation
carriers, it is notable that both SCZ cases carrying de novo LOF
mutations in SETD1A also manifest symptoms consistent with
a secondary diagnosis of obsessive-compulsive disorder
(OCD). Detailed description of the clinical presentation of these
two individuals is available in Supplemental Information. For
both, SCZ is the primary lifetime diagnosis and the one associ-
ated with their long-term disability. Overall, clinical information
Figure 1. Two De Novo LOF Indels in SETD1A
(A) Two de novo LOF indels in the SETD1A gene confirmed by Sanger
sequencing. (B) Structure of the SETD1A gene and the SETD1A protein along
with the positions of the two LOF indels. The de novo frameshift indel variant
(D424fs) (left) creates an early stop codon and leads to protein truncation. The
de novo indel variant c.4582-2_4582-1 del2 variant (right) changes the ca-
nonical splice acceptor site sequence adjacent to exon 16 from AG to GG.
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231 probands in our SCZ cohort, with 17 probands meeting full
diagnostic criteria for secondary, comorbid OCD. The proportion
of subjects with OCD in our SCZ cohort (17/205, 8.3%) is within
the range reported in previous studies (7.8%–26%; Bottas
et al., 2005). Given the number of subjects with comorbid OCD
in our SCZ cohort, occurrence of de novo LOF mutations in
SETD1A was significantly associated with SCZ comorbid with
OCD (p = 0.002, Barnard’s test). Whether this highly similar
phenotypic outcome suggests that patients with LOF mutations
in SETD1A could define a new clinical subtype of SCZ comorbid
with OCD symptoms (Bottas et al., 2005) remains to be deter-
mined by additional sequencing studies of larger cohorts of
both SCZ and OCD patients well-phenotyped for psychotic and
obsessive-compulsive symptoms.
Damaging De Novo Variants Highlight a Role of
Chromatin Regulators in SCZ
Further analysis aiming at prioritizing genes and variants for their
likely pathogenicity provided additional evidence for a role of
both de novo damaging mutations and chromatin regulators.
Specifically, application of a recently established scoring sys-
tem that makes use of human polymorphism data and reflects
the intolerance of each gene against functional genetic variation
in the general human population (residual variation intolerance
score [RVIS]) (Petrovski et al., 2013), to all de novo mutations
observed in individuals with SCZ in our and other studies (Girard
et al., 2011; Gulsuner et al., 2013; Xu et al., 2012), as well as incontrol individuals from family-based whole-exome sequencing
(WES) studies for SCZ, autism spectrum disorders (ASDs), and
intellectual disability (ID) (Gulsuner et al., 2013; Iossifov et al.,
2012; O’Roak et al., 2012b; Rauch et al., 2012; Sanders et al.,
2012; Xu et al., 2012), revealed significant enrichment of genes
intolerant to variation among the genes hit by de novo LOF
and missense variants (but not by de novo silent variants) in
cases (Figure S3A). No significant enrichment of any type of
de novo variant was observed within the control samples.
Two-dimensional (2D) plotting analyses that used the RVIS per-
centiles for genes (y axis) and PolyPhen-2 quantitative scores
(Adzhubei et al., 2010) for missense mutations (x axis) revealed
that de novo missense variants located within genes intolerant
to variation and predicted to be damaging by PolyPhen-2 (quan-
titative score R 0.95) are enriched in cases and therefore are
more likely to contribute to disease risk (Figure S3B). A similar
pattern of excess of genes intolerant to variation among genes
hit by functional de novo mutations was also reported in cohorts
ascertained for epilepsy, ID, and ASD (Petrovski et al., 2013),
suggesting that intolerant genes carrying functional variants,
including LOF ones, are more likely to be associated with
disease.
Based on these observations, in the combined data set of
family-basedWES studies of SCZ,we selected a total of 62 genes
thatare intolerant tovariationandharbordenovoLOFordamaging
missense (PolyPhen-2 scoresR 0.95) variants: 38 genes from our
studies (36 from the Xu et al., 2012 study plus SETD1A and ITPR2
identified in thecurrent analysis) aswell as25genes fromtwoother
studies (Girard et al., 2011; Gulsuner et al., 2013) (de novo
damaging variants in KIAA1109 were found across data sets).
Gene set enrichment analysis using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) (Huang et al.,
2009) revealed ‘‘chromatin regulator’’ as the most significantly
enriched term among these 62 genes (Figure S4A and Table S2,
also see Supplemental Information). Direct and indirect interac-
tions among chromatin regulator genes harboring de novo
damaging variants, including SETD1A, RBBP5, TRRAP, UBR5,
KDM2B, and KDM5C, are shown in Figure S4B.
The Inherited Component of SCZ Risk Is Enriched in
Rare LOF Variants
Recent WES studies in ASD provided evidence that inherited
LOF mutations were enriched in affected individuals (Lim et al.,
2013; Yu et al., 2013). Therefore, detailed analysis of rare
inherited variants promises to provide important insights toward
our understanding of the familial component of SCZ risk. To
evaluate evidence for such etiologies in SCZ, we studied the
transmission patterns of common and rare SNVs and indel vari-
ants identified from our WES data.
Because recent whole-genome and exome studies suggested
that many deleterious and disease-related variants, especially
LOF variants, exist at low frequency in the human population
(Lim et al., 2013; MacArthur et al., 2012; Abecasis et al., 2012;
Zhu et al., 2011), we first partitioned the variants into disjoint
classes according to their minor allele frequencies (MAF) in the
parents as follows: private variants, observed only once in the
parents; rare variants, observed more than once and MAF %
0.05; common variants, MAF > 0.05.Neuron 82, 773–780, May 21, 2014 ª2014 Elsevier Inc. 775
Table 2. Numbers of Transmitted and Untransmitted Alleles in
Cases and Controls
Cohort Transmitted Untransmitted T:U ratio
RTR
(Case/
Control) p Value
Loss-of-Function Variants (Nonsense, Canonical Splice Site, and
Frameshift Variants)
Private (hit once in parental population)
Cases 1,682 1,945 0.86 1.49 0.0086
Controls 159 274 0.58 – –
Rare (nonprivate and frequency% 0.05)
Cases 5,948 7,168 0.83 1.31 0.0051
Controls 902 1,425 0.63 – –
Common (frequency > 0.05)
Cases 26,350 27,724 0.95 1.08 0.037
Controls 3,732 4,231 0.88 – –
MODERATE-Effect Variants
Private
Cases 26,558 25,250 1.05 0.99 0.607
Controls 2,286 2,155 1.06 – –
Rare
Cases 146,052 158,361 0.92 1.10 0.022
Controls 20,603 24,663 0.84 – –
Common
Cases 920,641 958,085 0.96 1.02 0.023
Controls 127,551 135,706 0.94 – –
LOW-Effect Variants
Private
Cases 16,622 15,249 1.09 0.99 0.361
Controls 1,464 1,335 1.10 – –
Rare
Cases 129,196 136,780 0.94 1.05 0.176
Controls 17,610 19,562 0.90 – –
Common
Cases 1,148,993 1,177,446 0.98 1.01 0.058
Controls 159,769 165,749 0.96 – –
T:U ratio, transmitted to untransmitted ratio; RTR, relative transmission ratio
(T:U ratio in cases/T:U ratio in controls). Detailed definition forMODERATE-
and LOW-effect variants are described in the Supplemental Experimental
Procedures. p values were calculated by one-sided permutations.
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used the SnpEff software (Cingolani et al., 2012). By following the
definition of functionality of variants provided in this software, we
identified three classes: nonsense variants, variants disrupting
start and stop codons, canonical splice site variants, and frame-
shift variants were classified as ‘‘LOF’’ variants; missense vari-
ants and in-frame indels were classified as ‘‘MODERATE’’-effect
variants; and silent variants, variants generating start codons in
untranslated regions, and nonsynonymous variants generating
alternative start codons were classified as ‘‘LOW’’-effect
variants.
When we analyzed the transmission (number of transmissions
from parents to offspring) to untransmission (number of untrans-776 Neuron 82, 773–780, May 21, 2014 ª2014 Elsevier Inc.missions) ratio (T:U ratio) of LOF variants, we observed a
tendency toward undertransmission in both cases and controls,
i.e., T:U < 1 (Table 2; private LOFs: 0.86, rare LOFs: 0.83 and
common LOFs: 0.95 in cases; private LOFs: 0.58, rare LOFs:
0.63 and common LOFs: 0.88 in controls). A T:U ratio of 1 is
expected for neutral loci and it is what we observe for the com-
mon synonymous (LOW-effect) variants (T:U = 1) (Table 2).
There are several possible explanations for the observed distor-
tion in the transmission ratios of the LOF variants. One possibility
is that this is the result of selection acting against these LOF var-
iants, a mutation load-reducing mechanism that facilitates elim-
ination of deleterious mutations per generation and maintains
higher mean fitness. For example, if some of these variants are
associated with embryonic lethality or early onset of deleterious
developmental defects (Edmonds et al., 1982), some of the
carriers could be eliminated immediately in the next generation.
Selection may also be acting prior to fertilization in the form of
higher failure rate in gametogenesis, lower chance for fertilization
(Otto and Hastings, 1998), or in the form of cellular processes
related to selfish spermatogonial selection (Goriely et al.,
2013). In addition, the combination of LOF variants from the
two parents in the offspring may lead to more deleterious effects
(Crow, 2000). Finally, as we generally collected subjects without
severe comorbid diseases or developmental disorders for both
controls and cases, LOF variants linked to such maladies should
be represented less frequently among the transmitted alleles.
Although we observed global undertransmission of LOFs in
both cases and controls, the deviation from the 1:1 ratio was
more attenuated in cases than in controls. Therefore, we then
compared the T:U ratio in cases and controls to calculate the
relative transmission ratio (RTR = T:U ratio in cases/T:U ratio in
controls). Since sequencing and genotyping errors are expected
to affect cases and controls equally, contrasting T:U ratios in
cases versus controls should provide a robust result. We
observed significantly higher RTRs than expected for all allele
frequency classes of LOF variants (Table 2; private LOFs:
RTR = 1.49, p = 0.0086; rare LOFs: RTR = 1.31, p = 0.0051;
common LOFs: RTR = 1.08, p = 0.037, one-sided permutation
test). These results suggest that LOF variants identified in cases,
especially the private and rare ones, are enriched in disease-
causing variants.
To further confirm that our observation was not due to errors in
genotyping calls, we analyzed ‘‘MODERATE’’-effect variants and
‘‘LOW’’-effect variants. Unlike LOF variants, the T:U ratios for
MODERATE- and LOW-effect variants were close to 1:1 for all
allele frequency classes (Table 2). Therefore, the global under-
transmission of LOF variants that we observed is unlikely due
to sequencing errors but rather to selection acting against the
LOF variants. When we calculated RTRs, we observed sig-
nificantly higher RTRs for the rare and common MODERATE-
effect variants, but the effect sizes observed were more modest
than LOFs (Table 2; private MODERATE: RTR = 0.99, p = 0.607;
rare MODERATE: RTR = 1.10, p = 0.022; common MODERATE:
RTR = 1.02, p = 0.023, one-sided permutation test). For the var-
iants with LOW effect, we did not obtain any significant results
(Table 2). These findings indicate less contribution from variants
classified as MODERATE- or LOW-effect to the disease etiology
than from LOF variants. We also performed an analysis
Figure 2. Prominent Overtransmission of Private LOF Variants in
Intolerant Genes
Relative transmission ratios (RTRs) are displayed for variants categorized by
their functionality (blue: loss-of-function [LOF] variants; red: MODERATE-
effect variants; and green: LOW-effect variants), minor allele frequencies
(private, rare, or common), and gene intolerance. Detailed definition for LOF,
MODERATE-, and LOW-effect variants is provided in the Supplemental
Experimental Procedures. *p < 0.05. Error bars indicate 95% confidential in-
tervals. p values for RTRs were calculated by one-sided permutation analysis
with random shuffling of the case-control status.
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the observed results were not influenced by the combination
of two population groups (Table S3, and Supplemental
Information).
Application of RVIS provided further evidence for a role of
selection pressure in shaping the transmission patterns of in-
herited variants. We observed further increase in RTR for private
LOF variants in genes intolerant to functional variation (Figure 2;
RTR = 2.13, p = 0.0193, one-sided permutation test) compared
to private LOFs in all genes (RTR = 1.49). RTR for private LOF var-
iants in tolerant genes was 1.35 (p = 0.025). Difference of RTRs
between private LOF variants in intolerant and tolerant genes
showed marginal significance (p = 0.054). By contrast, a differ-
ence of RTRs between intolerant and tolerant genes was not
apparent for other classes of variants (rare and common LOFs,
all categories of missense and silent variants). These results sug-
gest that private LOFs in intolerant genes in cases aremore likely
to contribute to disease etiology than other variants. It should be
also noted that global undertransmission of private and rare LOF
variants was prominent for intolerant genes both in cases and
controls (private LOF variants: T:U = 0.81 in cases and 0.38 in
controls, rare LOF variants: T:U = 0.57 in cases and 0.41 in con-
trols), further indicating that the observed global undertransmis-
sion of LOF variants is not due to sequencing errors.
We also asked whether the load of inherited LOF variants
correlates with four clinical variables (see above, also described
in Supplemental Experimental Procedures) and observed a
significant correlation between severity scores of the disease
and per-individual number of private LOF variants (p = 2.77 3
105, Spearman’s rank correlation r = 0.29). This finding high-
lights the importance of private inherited LOFs for disease
manifestation. Thus, both analysis of transmission patterns andphenotypic correlations suggest that the inherited component
of SCZ risk is enriched in private LOF variants, especially ones
in genes intolerant to functional variation. A gene set enrichment
analysis showed that despite high genetic heterogeneity, there is
an enrichment of a few biological processes and/or functions
among such genes, most notably enrichment of terms related
to ATPase activity (see Supplemental Information and Table S4).
Finally, to explore individual promising candidate genes
further, we cross-compared the list of intolerant genes harboring
at least one private LOF variant in SCZ with lists of candidate
genes from previously published literature (see Supplemental
Information and Table S5). We found several genes in common
that represent promising candidate genes worthy of follow-up
analysis. In particular, when we cross-compared the list of intol-
erant genes harboring private LOFs with previously published
literature on CNVs associated with neuropsychiatric and neuro-
developmental diseases (Malhotra and Sebat, 2012), we found
two genes (LZTR1 and RFC2) in common. LZTR1, encoding a
protein exclusively localized to theGolgi network helping stabilize
the Golgi complex (Nacak et al., 2006), is located within the 3-Mb
22q11.2 deletion locus, a finding consistent with recent evidence
establishing a strong link between the Golgi apparatus and
neuronal phenotypes associated with the 22q11.2 microdeletion
(Mukai et al., 2008; Xu et al., 2013). RFC2 is located on the chro-
mosome 7q11.2Williams-Beuren syndrome (WBS) critical locus,
encodes for a protein playing a role in response to DNA damage,
and may be involved in microcephaly and growth retardation
observed in WBS patients (Merla et al., 2010). This finding is
also consistentwith recent findings implicatingDNA repairmech-
anisms in the pathogenesis of SCZ and ASD (Ionita-Laza et al.,
2014).
DISCUSSION
In this study, we performed a systematic investigation of the role
of both de novo and inherited LOF variants in order to elucidate
the role that gene-disruptive events play in the genetic architec-
ture of SCZ.
We confirmed an excess of de novo LOFs in SCZ patients and
identified a single gene (SETD1A) harboring two de novo LOF
indels in two individuals with SCZ. SETD1A encodes a catalytic
subunit of the histone methyltransferase protein complex,
named Set/COMPASS (complex protein associated with Set1).
This complex mediates mono-, di-, and trimethylation of H3K4,
a mark of active gene transcription (Miller et al., 2001; Roguev
et al., 2001). In humans, Set/COMPASS is comprised of one of
the six catalytic subunits (SETD1A, SETD1B, KMT2A [also
known as MLL], KMT2D [MLL2], KMT2C [MLL3], and KMT2B
[MLL4]), four common subunits (WDR5, RBBP5, ASH2L, and
DPY30), and several subtype-specific proteins (Mohan et al.,
2010; Shilatifard, 2012). Interestingly, de novo mutations in other
subunits comprising Set/COMPASS have been reported in SCZ
and ASD cases: a missense variant in RBBP5 in SCZ (Gulsuner
et al., 2013), as well as a nonsense variant in KMT2C and a
missense variant in KMT2A in ASD (Neale et al., 2012; O’Roak
et al., 2012b). It is also noteworthy that the ATP-dependent
chromatin helicase CHD8, in which recurrent de novo LOF
mutations have been identified in ASD patients (O’Roak et al.,Neuron 82, 773–780, May 21, 2014 ª2014 Elsevier Inc. 777
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COMPASS and plays a role in the regulation of H3K4 trimethyla-
tion (Yates et al., 2010).
Implication of SETD1A involvement, as well as the observed
enrichment of chromatin regulators among genes hit by de
novo damaging variants in SCZ, are in line with accumulating
data indicating a role of chromatin-related genes in various
psychiatric and neurodevelopmental disorders (Ben-David and
Shifman, 2013; Ronan et al., 2013). Involvement of chromatin
modification pathways in SCZ was also suggested from analysis
integrating data from de novo CNVs, de novo SNVs, and
genome-wide association studies (GWASs) (Gilman et al.,
2012). Although there was no statistically significant enrichment
of chromatin-related pathways among genes at loci identified in
the largest GWAS for SCZ so far, some genes involved in
chromatin regulation, such as PBRM1 and SETD8, were found
in the proximity of SNPs with genome-wide significant associa-
tion (Ripke et al., 2013).
H3K4 trimethylation, in particular, is known to be essential for
neuronal differentiation (Wynder et al., 2005) and fear memory
formation (Gupta et al., 2010). The H3K4 trimethylation status
in prefrontal cortex neurons is dynamically regulated from the
late prenatal period to early adulthood (Shulha et al., 2013). Inter-
estingly, there are reports of decreased H3K4 trimethylation at
the GAD1 promoter region in the prefrontal cortex of female
SCZ patients (Huang et al., 2007), as well as of upregulation of
Gad1 H3K4 trimethylation induced by clozapine but not by
haloperidol (Huang et al., 2007). It is also noteworthy that a de
novo LOF variant in KDM5C, encoding JARID1C that mediates
demethylation of H3K4, was found in another SCZ subject in
our cohort (Xu et al., 2012). Mutations in KDM5C have also
been linked to nonsyndromic X-linked mental retardation (Jen-
sen et al., 2005).
ApplicationofRVIS identifiedSETD1Awithin the first percentile
of the most intolerant genes against functional variants including
LOF and missense variants (Petrovski et al., 2013). When we
calculated in the same manner intolerance scores specifically
against LOF variants using data from Exome Variant Server
(http://evs.gs.washington.edu/EVS), SETD1A was included in
the fourthpercentile of thegenesmost intolerant against LOFvar-
iants. In addition, there is noLOFvariant disruptingSETD1A in the
1000 Genomes Project database (Abecasis et al., 2012), another
large-scale data source of human genetic variation. The high
intolerance of SETD1A specifically against LOF variants further
supports that the identification of two de novo LOF mutations in
our SCZ cohort is unlikely to have occurred by chance.
Our current analysis using PRISM and Pindel revealed five
previously unidentified de novo LOF indels. The fact that these
LOFs were not identified in our previous analysis using Dindel
and its default filtering parameters is primarily due to the low
coverage of these variant sites in relation to their highGCcontent
or their complex structure. Specifically, for four of these LOFs
(CEP104, INHBC, and the two SETD1A indels), the coverage of
their genomic position was 53–133, with 56–70 GC% content
in the surrounding 100 bp regions (50 bp upstream and 50 bp
downstream). For the fifth LOF (ITPR2 indel), the genomic posi-
tion was well covered (423 coverage, GC% content = 51), but
the variant was probably missed in our previous analysis778 Neuron 82, 773–780, May 21, 2014 ª2014 Elsevier Inc.because of its complexity and relatively long length (a combina-
tion of an 11 bp insertion and a 3 bp deletion). Therefore, our
current analysis using two different software and custom filtering
criteria may be advantageous for identifying indels with complex
structures or at low coverage regions. It is also notable that
the SETD1A frameshift indel and the CEP104 indel were solely
identified by PRISM and Pindel, respectively. This indicates
that the sensitivity of detecting de novo indels could be
increased substantially by using multiple software.
Identification of relatively increased transmission of private
and rare inherited LOF variants in SCZ probands highlighted
the significance of such events as risk factors for SCZ, while
correlation of mutational load with disease severity implicated
them in clinical outcome. Similar to the de novo CNVs and
SNVs, these mutations are distributed across many different
genes and therefore would have been missed through previous
association or linkage studies. Results from our WES family-
based analysis are consistent with recent case-control studies
performing targeted resequencing of candidate genes, which
also reported excess of rare LOF variants in SCZ patients (Hu
et al., 2013; Kenny et al., 2013).
Results from the current study and the findings in other studies
for de novo SNVs and indels (Girard et al., 2011; Xu et al., 2011,
2012) collectively highlight the significance of LOF mutations in
the overall genetic etiology of SCZ. In addition, LOF events
provide further collective insight into the heritable component of
SCZ, which has not yet been accounted for by de novo CNVs
and SNVs. Finally, identification of SETD1A as one of the first
genes recurrently hit by de novo LOF mutations in SCZ, strongly
suggests that further studies using large sample sets enriched in
truly sporadic cases as well as intensive analysis of currently
available data sets focusing on LOF variants will lead to the dis-
covery of additional recurrently affectedgenes, a key step toward
elucidating the neural mechanisms underlying susceptibility to
SCZ and designing novel therapies (Karayiorgou et al., 2012).
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